Aethlon Medical (NASDAQ:AEMD) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a note issued to investors on Sunday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Aethlon Medical in a report on Friday, November 15th.

Aethlon Medical Stock Performance

NASDAQ:AEMD opened at $0.40 on Friday. The stock has a market capitalization of $5.64 million, a PE ratio of -0.14 and a beta of 1.74. Aethlon Medical has a fifty-two week low of $0.24 and a fifty-two week high of $2.35. The company has a fifty day moving average of $0.40 and a two-hundred day moving average of $0.45.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.